search
Back to results

Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System

Primary Purpose

Vascular Disease, Peripheral

Status
Unknown status
Phase
Early Phase 1
Locations
Chile
Study Type
Interventional
Intervention
Endovascular Intervention
Sponsored by
PeriTec Biosciences Ltd.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vascular Disease, Peripheral

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with claudication or ischemic rest pain(Rutherford Categories 2-4)
  • The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis
  • Patient has a signed and dated informed consent
  • Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8
  • Life expectancy greater than one year
  • The ability to comply with protocol follow up requirements and required testing
  • Angiographic lesion requirements assessed at time of procedure

    • Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis
    • Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint
    • Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention
    • Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath

Exclusion Criteria:

  • Untreated iliac artery in-flow limiting lesion
  • Significant proximal common femoral or superficial femoral artery disease above or below target lesion
  • Any previously treated superficial femoral artery lesion
  • Any previous stenting or surgery in the target vessel
  • Femoral or popliteal aneurysm
  • Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc)
  • Serum creatinine >2.5 mg/dl
  • Any previously known coagulation disorder, including hypercoagulability
  • Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)

Sites / Locations

  • Pontificia Universidad Catolica de ChileRecruiting

Outcomes

Primary Outcome Measures

Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events

Secondary Outcome Measures

Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization

Full Information

First Posted
October 10, 2007
Last Updated
November 27, 2007
Sponsor
PeriTec Biosciences Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00542646
Brief Title
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Official Title
Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System
Study Type
Interventional

2. Study Status

Record Verification Date
November 2007
Overall Recruitment Status
Unknown status
Study Start Date
November 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
PeriTec Biosciences Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The occurrence of Peripheral Vascular Disease has been increasing which includes the large artery in the upper leg called Superficial Femoral Artery (SFA). The Peritoneal Lined Stent has been developed as a new method for treating narrowed area in the SFA. This research study will determine the safety and effectiveness of the Peritoneal Lined Stent in keeping th Superficial Femoral Artery open and allowing blood to flow in the leg.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vascular Disease, Peripheral

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Endovascular Intervention
Intervention Description
Peritoneal Lined Stent Endovascular Intervention
Primary Outcome Measure Information:
Title
Efficacy: Primary patency postprocedure and technical success Safety: Composite of major procedural adverse events
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Primary Patency Primary Assisted Patency Secondary Patency Clinical Success Major Amputations Target Vessel Revascularization Target Lesion Revascularization
Time Frame
3 Months Intervals except for Target Lesion Revascularization at 12 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with claudication or ischemic rest pain(Rutherford Categories 2-4) The angiogram will need to have been performed confirming superficial femoral artery short segment occlusion(<5cm first two patients and <10cm there on) or high grade(>50%)stenosis Patient has a signed and dated informed consent Patient has a resting ABI <0.9 or an abnormal exercise ABI if resting ABI is normal. Patients with incompressible arteries (ABI >1.2) must have TBI <0.8 Life expectancy greater than one year The ability to comply with protocol follow up requirements and required testing Angiographic lesion requirements assessed at time of procedure Lesion of the superficial femoral artery with a short segment occlusion(<5cm first two patients and <10cm there on) or high grade (>50%) stenosis Target lesion 1 cm below profunda/superficial femoral artery origin and 3cm above knee joint Angiographic evidence of a minimum of at least one tibial with continuous artery runoff to the ankle that does not require intervention Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel, and successful placement of 9 french(Fr) sheath Exclusion Criteria: Untreated iliac artery in-flow limiting lesion Significant proximal common femoral or superficial femoral artery disease above or below target lesion Any previously treated superficial femoral artery lesion Any previous stenting or surgery in the target vessel Femoral or popliteal aneurysm Non-Atherosclerotic disease resulting in occlusion (e.g. embolism, vasculitis,etc) Serum creatinine >2.5 mg/dl Any previously known coagulation disorder, including hypercoagulability Severe medical co-morbidities or other medical condition (for example untreated coronary heart disease and congestive heart failure, severe chronic obstructive pulmonary disease, metastasis malignance, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rajesh Khosla, MBA
Phone
216.444.1293
Email
rkhosla@peritecbio.com
First Name & Middle Initial & Last Name or Official Title & Degree
Linda Modzelewski
Phone
216.444.5004
Email
lm@peritecbio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timur Sarac, MD
Organizational Affiliation
PeriTec Bioscience Ltd
Official's Role
Study Director
Facility Information:
Facility Name
Pontificia Universidad Catolica de Chile
City
Santiago
Country
Chile
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Albrecht Kramer, MD
Phone
562.354.3233
Email
kramer@med.puc.cl

12. IPD Sharing Statement

Citations:
PubMed Identifier
16643070
Citation
Carnevale K, Ouriel K, Gabriel Y, Clair D, Bena JF, Silva MB, Sarac TP. Biological coating for arterial stents: the next evolutionary change in stents. J Endovasc Ther. 2006 Apr;13(2):164-74. doi: 10.1583/05-1710R.1.
Results Reference
background
PubMed Identifier
15838485
Citation
Sarac TP, Carnevale K, Smedira N, Tanquilut E, Augustinos P, Patel A, Naska T, Clair D, Ouriel K. In vivo and mechanical properties of peritoneum/fascia as a novel arterial substitute. J Vasc Surg. 2005 Mar;41(3):490-7. doi: 10.1016/j.jvs.2004.11.033.
Results Reference
background

Learn more about this trial

Pilot Study to Evaluate the Safety and Preliminary Efficacy of the Peritec Peritoneal Lined Stent and Delivery System

We'll reach out to this number within 24 hrs